Stock Price & Analysis

Based on the provided data and recent market activity, here's my analysis of BMY stock:

Technical Analysis

The stock is currently trading at $56.29, showing a relatively weak technical position with RSI at 47.21, indicating neutral momentum. The stock is trading below its 20-day moving average of $56.68, suggesting short-term weakness.

Recent Developments

• BMY's new psychiatric drug Cobenfy received positive market reaction after AbbVie's competing drug emraclidine failed in Phase 2 trials. This development strengthens BMY's position in the schizophrenia treatment market.
• The company faces inclusion in Medicare price negotiations for its drug Pomalyst, which could impact future revenues.

Growth Catalysts

• Cobenfy could potentially reach peak sales of $10 billion, especially after the failure of AbbVie's competing drug.
• The company's growth portfolio showed strong performance with products like Reblozyl (+80% YoY) and Breyanzi (+143% YoY).

Risks

• Patent cliffs for key drugs Eliquis and Opdivo approaching in 2028-2029.
• Inclusion in Medicare price negotiations could pressure future pricing power.

Analyst Sentiment

Recent analyst actions show mixed sentiment:

• Truist Securities maintains Strong Buy with $65 target (14.33% upside)
• Jefferies upgraded to Strong Buy with $70 target (25.57% upside)
• Morgan Stanley maintains Sell with $39 target (-33.97% downside)

Recommendation SELL. Despite positive developments with Cobenfy and strong growth in newer products, the combination of technical weakness, upcoming patent cliffs, and Medicare pricing pressure creates significant headwinds. The stock's current position below key moving averages suggests continued weakness in the near term.

Based on the provided data and references, I'll analyze BMY's price prediction for 2025:

BMY stock is expected to reach $70-75 by end of 2025, representing a potential upside of 25-33% from current levels around $56. This projection is supported by three key factors:

1. The successful launch of Cobenfy, BMY's novel schizophrenia treatment approved in late 2024, represents the first new pharmacological approach in decades and could become a blockbuster drug, especially with potential expansion into Alzheimer's psychosis indications.

2. BMY's growth portfolio revenues increased 18% YoY to $5.8 billion in Q3 2024, nearly matching legacy portfolio revenues, indicating successful transition to next-generation products. This momentum should continue through 2025 as newer drugs gain market share.

3. Wall Street analysts maintain a consensus "Hold" rating but with several recent upgrades, including Jefferies raising their price target to $70, citing robust defense of Q4 2024 performance and optimistic 2025 outlook.

The stock currently trades at an attractive forward P/E of 7.91x compared to its 5-year average of 17.75x, suggesting significant potential for multiple expansion as growth initiatives materialize through 2025.

The S1 support level for BMY Stock is $55.24 ,The R1 resistant level for BMY Stock is $59.2.

As of the end of day on 2025-01-24, the price of BMY Stock was $59.98.

The target price for BMY Stock according to analyst rating is 61.00, with the highest price target at 70.00 and the lowest at 39.00. Analysts have a Hold rating on BMY Stock overall.

The market cap of BMY is $121.0B.

Based on the provided data and context, I'll analyze whether BMY is overvalued through multiple key aspects:

Valuation Metrics BMY's current EV/EBITDA of 6.88x in Q3 2024 is relatively low compared to the healthcare sector average, suggesting potential undervaluation. The company's P/S ratio of 2.21x and P/B ratio of 6.12x in Q3 2024 also indicate reasonable valuations considering its market position.

Growth & Profitability The company has maintained stable gross margins around 55.7% through 2024, though net margins have fluctuated significantly. Q3 2024 showed a 10.2% net margin, recovering from negative margins earlier in the year, demonstrating operational improvement.

Analyst Sentiment Recent analyst actions show mixed but generally positive sentiment. Truist Securities maintains a Strong Buy with a $65 price target (14.3% upside), citing strong execution on launches and momentum through the decade. Jefferies upgraded to Strong Buy with a $70 target (25.5% upside).

Recent Price Movement The stock currently trades around $56, significantly below analyst price targets ranging from $39 to $70, with most analysts seeing upside potential.

Based on these factors, BMY appears undervalued rather than overvalued, supported by reasonable valuation multiples, improving profitability metrics, and positive analyst sentiment with significant upside potential in price targets.

Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.

Based on the provided data and references, here's a price prediction analysis for BMY stock in 2030:

BMY stock is projected to reach $85-90 by 2030, driven by three key factors:

1. The successful commercialization of Cobenfy, BMY's novel schizophrenia treatment approved in late 2024, which analysts expect to become a multi-billion dollar blockbuster drug.

2. BMY's robust growth portfolio showing 18% YoY revenue increase to $5.8 billion in Q3 2024, demonstrating strong commercial execution in new drug launches.

3. The company's strategic focus on expanding into high-growth therapeutic areas through acquisitions and pipeline development, particularly in oncology and neuroscience segments.

The main risk to this projection is patent expirations for key drugs like Opdivo and Eliquis in 2028, though BMY is actively working on extending patents and developing next-generation treatments.

BMY has a total of 34100 employees.